Medline, Inc. MDLN Net proceeds from sales of subsidiary shares

Net proceeds from sales of subsidiary shares at other companies

MedtronicMDT

$134.5M—

Revenue$7.4B+10.7%

Gross profit$1.8B+0.9%

Operating income$422.0M-26.1%

Net income$239.0M-25.1%

EPS (diluted)$0.16—

Cash & equivalents$2.2B+166%

Total debt$12.6B—

Total equity$11.3B—

Total assets$39.0B—

Operating cash flow$412.0M-39.6%

CapEx$96.0M-2.0%

Free cash flow$316.0M-45.9%

Market cap$30.39B—

Enterprise value$40.71B—

P/E36.1×—

P/S1.1×—

Gross margin27.4%+1.5pp

Operating margin8.5%+2.3pp

Net margin4.6%+2.7pp

Return on equity7.7%—

Debt / equity1.1×—

Current ratio4.4×—

Reported directly by Medline, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.

The official record: Medline, Inc. ’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Medline, Inc. 's net proceeds from sales of subsidiary shares?: Medline, Inc. (MDLN) reported net proceeds from sales of subsidiary shares of $1.76B in Q4 2025.